ClinicalTrials.gg
Enrolling by invitationNCT06641843Updated Oct 15, 2024

Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease

An observational study in Kawasaki Disease, Cardiovascular Disease and Anomalous Origin of Coronary Artery, sponsored by West China Second University Hospital. Enrolling by invitation at 1 site in China. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by West China Second University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · China.

Started
2024
with 1 other
Observational
8 of 16
4 open now
Registered
10th of 16
by date
Lead sponsor
2 of 16
West China Second University Hospital

Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, this one is one of 2 that started in 2024, is one of 8 observational ones, and was the 10th registered.

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

Browse Mucocutaneous Lymph Node Syndrome studies →

Open to participants now

8 of the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: Up to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, or all of them as a file.
02

Study summary

the goal of this observational study is to evaluate myocardial ischemia and myocardial microcirculation dysfunction in children with cardiovascular disease by myocardial stress perfusion imaging.

During their disease progress, participants will undergo myocardial stress perfusion, laboratory tests when hospitalization and follow-up, and the baseline data will be collected in the admission. all the above examination data will be analysed to identify early subclinical myocardial changes and evaluate the value of magnetic resonance myocardial stress perfusion in predicting prognosis.

03

Conditions studied

  • Kawasaki Disease
  • Cardiovascular Disease
  • Anomalous Origin of Coronary Artery
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

From September 2024 to Jaunary 2034, pediatric patients diagnosed with cardiovascular disease were prospectively recruited from West China Second University Hospital, Sichuan University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart disease.

Exclusion criteria

Exclusion Criteria:

  • Mental abnormalities or poor compliance ; heart, kidney and other important organs were seriously incomplete.
  • MRI examination ; gadolinium contrast agent contraindications ; claustrophobia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • patients diagnosed with cardiovascular disease

    Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart diseases

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovscualr events

    Major adverse cardiovascular events including cardiac death, transient ischemic attack or stroke, myocardial infarction, arrhythmia, heart failure, severe valvular disease, percutaneous coronary intervention, coronary artery bypass graft, and other cardiovascular surgery.

    Time frame: 10 years after the onset

07

Study locations

1 site
08

References and documents

Publications

  • Zhou W, Lee JCY, Leung ST, Lai A, Lee TF, Chiang JB, Cheng YW, Chan HL, Yiu KH, Goh VK, Pennell DJ, Ng MY. Long-Term Prognosis of Patients With Coronary Microvascular Disease Using Stress Perfusion Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2021 Mar;14(3):602-611. doi: 10.1016/j.jcmg.2020.09.034. Epub 2020 Nov 25. PubMed 33248966 ↗
  • Erbel C, Mukhammadaminova N, Gleissner CA, Osman NF, Hofmann NP, Steuer C, Akhavanpoor M, Wangler S, Celik S, Doesch AO, Voss A, Buss SJ, Schnabel PA, Katus HA, Korosoglou G. Myocardial Perfusion Reserve and Strain-Encoded CMR for Evaluation of Cardiac Allograft Microvasculopathy. JACC Cardiovasc Imaging. 2016 Mar;9(3):255-66. doi: 10.1016/j.jcmg.2015.10.012. PubMed 26965729 ↗
  • Shaw JL, Nelson MD, Wei J, Motwani M, Landes S, Mehta PK, Thomson LEJ, Berman DS, Li D, Bairey Merz CN, Sharif B. Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study. Int J Cardiol. 2018 Nov 1;270:48-53. doi: 10.1016/j.ijcard.2018.06.086. Epub 2018 Jun 22. PubMed 30041981 ↗
  • Park SM, Wei J, Cook-Wiens G, Nelson MD, Thomson L, Berman D, Handberg E, Petersen J, Anderson D, Pepine CJ, Merz CNB. Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. Eur Heart J Cardiovasc Imaging. 2019 Aug 1;20(8):875-882. doi: 10.1093/ehjci/jez044. PubMed 30904924 ↗
  • Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Nov 30;144(22):e368-e454. doi: 10.1161/CIR.0000000000001030. Epub 2021 Oct 28. PubMed 34709928 ↗
  • Ferrari R, Rosano G. 2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):331-332. doi: 10.1093/ehjcvp/pvaa006. No abstract available. PubMed 32154890 ↗
  • Aetesam-Ur-Rahman M, Brown AJ, Jaworski C, Giblett JP, Zhao TX, Braganza DM, Clarke SC, Agrawal BSK, Bennett MR, West NEJ, Hoole SP. Adenosine-Induced Coronary Steal Is Observed in Patients Presenting With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2021 Jul 6;10(13):e019899. doi: 10.1161/JAHA.120.019899. Epub 2021 Jun 30. PubMed 34187187 ↗
  • Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Oct 19;78(16):1655-1668. doi: 10.1016/j.jacc.2021.08.022. PubMed 34649703 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Jan 2034, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 15, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Jan 1, 2034
CompletionEst.
Sep 30, 2034
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06641843
Lead sponsor
West China Second University Hospital
Responsible party
Ling-Yi Wen (Principal Investigator, West China Second University Hospital) — Principal investigator
First posted
Oct 15, 2024
Start date
Sep 1, 2024
Primary completion
Jan 1, 2034 (estimated)
Completion
Sep 30, 2034 (estimated)
Last update
Oct 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion